S. Henry

发表

Preclinical development of antisense therapeutics

D. L. Cole, G. Hardee, A. Levin, 1999 .

Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys.

B. Monia, Shin-Young Park, S. Henry, 2013, Nucleic acid therapeutics.

Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies.

Shin-Young Park, S. Henry, Ki-Suk Kim, 2014, Journal of pharmacological and toxicological methods.

Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys

S. Henry, R. Yu, T. P. Prakash, 2016, Molecular therapy. Nucleic acids.

Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit.

A. Zutshi, A. Levin, D. Kornbrust, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys.

A. Levin, S. Henry, J. Leeds, 1998, Drug metabolism and disposition: the biological fate of chemicals.

Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteers Peripheral Blood Mononuclear Cells

S. Henry, B. Baker, T. Machemer, 2021, bioRxiv.

Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2′-MOE-ASOs

E. Hurh, S. Henry, R. Yu, 2017, Molecular therapy. Nucleic acids.

Lack of QT Prolongation for 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy Subjects

S. Henry, R. Yu, R. Geary, 2017, Nucleic acid therapeutics.

Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice

M. Graham, S. Henry, R. Yu, 2016, Molecular therapy. Nucleic acids.

Assessment of the Effects of ISIS 2302, an Anti-Sense Inhibitor of Human ICAM-1, on Cellular and Humoral Immunity in Mice

A. Levin, S. Henry, J. Mennear, 2006, Journal of immunotoxicology.

Non-CpG-Containing Antisense 2′-Methoxyethyl Oligonucleotides Activate a Proinflammatory Response Independent of Toll-Like Receptor 9 or Myeloid Differentiation Factor 88

S. Henry, S. Burel, J. Senn, 2005, Journal of Pharmacology and Experimental Therapeutics.

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.

D. Kornbrust, S. Henry, C. Auletta, 1997, Toxicology.

Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in mice.

P. Adamson, B. Monia, S. Henry, 2016, Immunobiology.

Impurities in Oligonucleotide Drug Substances and Drug Products.

S. Henry, A. Teasdale, J. Foy, 2017, Nucleic acid therapeutics.

Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.

G. Hardee, A. Levin, S. Henry, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Setting sights on the treatment of ocular angiogenesis using antisense oligonucleotides.

N. Dean, S. Henry, E. Marcusson, 2004, Trends in pharmacological sciences.

Scientific and Regulatory Policy Committee Points-to-consider Paper*

M. Leach, S. Henry, T. Zabka, 2015, Toxicologic pathology.

Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide.

A. Levin, D. Kornbrust, S. Henry, 2002, International immunopharmacology.

Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides.

S. Henry, B. Detrick, J. Hooks, 2001, Investigative ophthalmology & visual science.

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice.

A. Levin, D. Kornbrust, S. Henry, 1997, Antisense & nucleic acid drug development.

Toxicity of Oligodeoxynucleotide Therapeutic Agents

A. Levin, S. Henry, P. Nicklin, 1998 .

Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia.

B. Monia, S. Henry, T. Machemer, 2020, Nucleic acid therapeutics.

Correlation of Toxicity and Pharmacokinetic Properties of a Phosphorothioate Oligonucleotide Designed to Inhibit ICAM-1

A. Levin, S. Henry, M. Templin, 1999, Toxicologic pathology.

Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.

A. Levin, S. Henry, R. Geary, 1997, Anti-cancer drug design.

Unique O-Methoxyethyl Ribose-DNA Chimeric Oligonucleotide Induces an Atypical Melanoma Differentiation-Associated Gene 5-Dependent Induction of Type I Interferon Response

S. Freier, S. Henry, T. Machemer, 2012, Journal of Pharmacology and Experimental Therapeutics.

Scientific and Regulatory Policy Committee Points-to-consider Paper*

M. Leach, S. Henry, T. Zabka, 2015, Toxicologic pathology.

Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys.

B. Monia, S. Henry, J. Huh, 2012, Blood.

Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl–Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates

Y. Hua, A. Krainer, N. York, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Considerations for assessment of reproductive and developmental toxicity of oligonucleotide-based therapeutics.

D. Kornbrust, S. Henry, J. Cavagnaro, 2014, Nucleic acid therapeutics.

Local and systemic tolerability of a 2′O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey

J. McDonald, A. Gigliotti, M. Reed, 2014, Inhalation toxicology.

Comparison of the Class Effects of Antisense Oligonucleotides in CByB6F1-Tg(HRAS)2Jic and CD-1 Mice

S. Henry, J. Matson, S. Burel, 2018, Toxicologic pathology.

Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations

S. Henry, R. Geary, D. Norris, 2017, Journal of clinical pharmacology.

Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats.

D. Kornbrust, S. Henry, R. Bruner, 1997, Toxicology.

Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2’-MOE-Modified Antisense Oligonucleotide

J. Nolan, S. Henry, S. Burel, 2018, Toxicological sciences : an official journal of the Society of Toxicology.

Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc3-Conjugated Antisense Oligonucleotides

S. Henry, R. Yu, R. Geary, 2019, Expert opinion on drug metabolism & toxicology.

CpG and Non-CpG Oligodeoxynucleotides Induce Differential Proinflammatory Gene Expression Profiles in Liver and Peripheral Blood Leukocytes in Mice

A. Levin, S. Henry, T. Vickers, 2006, Journal of immunotoxicology.

Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?

A. Levin, S. Henry, R. Yu, 2001, Current opinion in investigational drugs.

Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents.

S. Crooke, A. Levin, S. Henry, 1997, Anti-cancer drug design.

Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.

A. Levin, S. Henry, D. Monteith, 1997, Anti-cancer drug design.

Toxicological properties of several novel oligonucleotide analogs in mice.

S. Crooke, S. Henry, J. Rojko, 1997, Anti-cancer drug design.

2′-O-(2-Methoxyethyl) Nucleosides Are Not Phosphorylated or Incorporated Into the Genome of Human Lymphoblastoid TK6 Cells

N. Gooderham, S. Henry, A. F. Saleh, 2018, Toxicological sciences : an official journal of the Society of Toxicology.

Pharmacokinetic and Pharmacodynamic Investigations of ION-353382, a Model Antisense Oligonucleotide: Using Alpha-2-Macroglobulin and Murinoglobulin Double-Knockout Mice.

S. Henry, R. Yu, R. Geary, 2016, Nucleic acid therapeutics.

Discovery and Early Clinical Development of ISIS-HTTRx, the First HTT-Lowering Drug to Be Tested in Patients with Huntington’s Disease (PL01.002)

S. Tabrizi, B. Leavitt, B. Landwehrmeyer, 2016 .

Intravitreous anti-raf-1 kinase antisense oligonucleotide as an angioinhibitory agent in porcine preretinal neovascularization

F. Orge, R. Danis, K. Stecker, 2003, Current eye research.

Sequence-specific 2'-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates

S. Henry, H. Gaus, J. Italiano, 2021, Haematologica.

Chronic Toxicity Assessment of 2'-O-Methoxyethyl Antisense Oligonucleotides in Mice.

Shin-Young Park, S. Henry, Tae-Won Kim, 2018, Nucleic acid therapeutics.

Species and pathway-specific activation of complement by a phosphorothioate oligonucleotide

S. Henry, T. Hugli, P. Giclas, 2000 .

Pharmacokinetic Properties of Phosphorothioate Oligonucleotides

A. Levin, S. Henry, R. Geary, 1997 .

Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers

Christopher E. Hart, H. Bui, S. Crooke, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Chemically modified oligonucleotides exhibit decreased immune stimulation in mice.

K. Stecker, S. Henry, C. Bennett, 2000, The Journal of pharmacology and experimental therapeutics.

An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice.

K. Stecker, D. Kornbrust, S. Cooper, 1997, The Journal of pharmacology and experimental therapeutics.

Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2′-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide–Triantenarry N-Acetyl-galactosamine Conjugate that Targets the Human Transmembrane Protease Serine 6

Shuling Guo, S. Henry, S. Burel, 2021, The Journal of Pharmacology and Experimental Therapeutics.

Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts

Christopher E. Hart, S. Freier, M. Sabripour, 2015, Nucleic acids research.

Inflammatory Non-CpG Antisense Oligonucleotides Are Signaling Thought TLR9 in Human Burkitt Lymphoma B Bjab Cells.

S. Damle, S. Henry, T. Machemer, 2022, Nucleic acid therapeutics.

Mechanism Driven Early Stage Identification and Avoidance of Antisense Oligonucleotides Causing TRL9 Mediated Inflammatory Responses in Bjab cells

S. Damle, S. Henry, T. Machemer, 2021, bioRxiv.

Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys.

A. Levin, S. Henry, R. Geary, 2000, Antisense & nucleic acid drug development.

Fomivirsen: clinical pharmacology and potential drug interactions.

Richard S Geary, S. Henry, R. Geary, 2002, Clinical pharmacokinetics.

Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits.

A. Levin, S. Henry, R. Yu, 2004, Birth defects research. Part B, Developmental and reproductive toxicology.

Toxicity of Antisense Oligonucleotides

A. Levin, S. Henry, M. Templin, 2001, Antisense Drug Technology.

Assessing unintended hybridization-induced biological effects of oligonucleotides

J. Burchard, S. Bartz, M. Lindow, 2012, Nature Biotechnology.

Assessment of the Effects of 2'-Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman Primates.

S. Bhanot, S. Henry, S. Burel, 2017, Nucleic acid therapeutics.

Overview of the Nonclinical Development Strategies and Class-Effects of Oligonucleotide-Based Therapeutics

D. Kornbrust, S. Henry, M. Templin, 2013 .

Toxicologic Properties of 2-O-Methoxyethyl Chimeric Antisense Inhibitors in Animals and Man

A. Levin, S. Henry, Tae-Won Kim, 2007 .

A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy

Mirjam N Trame, L. Lesko, I. Nestorov, 2018, CPT: pharmacometrics & systems pharmacology.

Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.

M. Pangburn, A. Levin, D. Kornbrust, 1997, The Journal of pharmacology and experimental therapeutics.

Chapter 28 – Overview of the Nonclinical Development Strategies and Class-Effects of Oligonucleotide-Based Therapeutics

D. Kornbrust, S. Henry, M. Templin, 2017 .

Predictive Dose-Based Estimation of Systemic Exposure Multiples in Mouse and Monkey Relative to Human for Antisense Oligonucleotides With 2′-O-(2-Methoxyethyl) Modifications

S. Henry, R. Yu, R. Geary, 2015, Molecular therapy. Nucleic acids.

Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2'-O-Methoxyethyl Modified Antisense Oligonucleotide.

J. Yee, S. Henry, J. Matson, 2016, Nucleic acid therapeutics.

Antisense Oligonucleotide Therapy in Diabetic Retinopathy

S. Henry, D. Boyer, J. Clement, 2009, Journal of diabetes science and technology.

The Distinct and Cooperative Roles of Toll-Like Receptor 9 and Receptor for Advanced Glycation End Products in Modulating In Vivo Inflammatory Responses to Select CpG and Non-CpG Oligonucleotides.

Shuling Guo, S. Henry, C. Bennett, 2017, Nucleic acid therapeutics.

Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide

B. Monia, S. Henry, T. R. Grossman, 2016, Molecular vision.

Drug-induced thrombocytopenia: mechanisms and relevance in preclinical safety assessment

S. Henry, Nianyu Li, P. Narayanan, 2019, Current Opinion in Toxicology.

Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice.

A. Levin, S. Henry, R. Yu, 2004, Birth defects research. Part B, Developmental and reproductive toxicology.

Inhibition of coagulation by a phosphorothioate oligonucleotide.

W. Novotny, D. Kornbrust, S. Henry, 1997, Antisense & nucleic acid drug development.

Potential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases

R. Danis, S. Henry, 2001, Expert opinion on pharmacotherapy.

Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs.

S. Henry, R. Yu, D. Verthelyi, 2022, Nucleic acid therapeutics.

Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotide.

A. Levin, S. Henry, J. Matson, 2002, Mutagenesis.

Mechanistic Understanding for the Greater Sensitivity of Monkeys to Antisense Oligonucleotide–Mediated Complement Activation Compared with Humans

P. Reynolds, M. Pangburn, S. Henry, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.

S. Henry, R. Yu, R. Geary, 2016, Nucleic acid therapeutics.

Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2′‐MOE and Phosphorothioate Modified Antisense Oligonucleotides

E. Hurh, S. Bhanot, S. Henry, 2022, Journal of clinical pharmacology.

Renal uptake and tolerability of a 2'-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey.

A. Levin, S. Henry, Mark Johnson, 2012, Toxicology.

Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase.

A. Levin, S. Henry, D. Monteith, 1997, Anti-cancer drug design.

Pharmacodynamics and Subchronic Toxicity in Mice and Monkeys of ISIS 388626, a Second-Generation Antisense Oligonucleotide That Targets Human Sodium Glucose Cotransporter 2

S. Henry, R. Yu, K. Chakravarty, 2012, Journal of Pharmacology and Experimental Therapeutics.

Inhibiting C-Reactive Protein for the Treatment of Cardiovascular Disease: Promising Evidence from Rodent Models

S. Oparil, M. Graham, R. Crooke, 2014, Mediators of inflammation.

EFFECTS OF INTRAVENOUS INFUSION OF PHOSPHOROTHIOATE OLIGONUCLEOTIDES ON COAGULATION, COMPLEMENT ACTIVATION AND HEMODYNAMICS

A. Levin, D. Kornbrust, S. Henry, 1997 .

Considerations for the Characterization and Interpretation of Results Related to Alternative Complement Activation in Monkeys Associated with Oligonucleotide-Based Therapeutics.

D. Kornbrust, S. Henry, J. Cavagnaro, 2016, Nucleic Acid Therapeutics.

Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.

A. Levin, S. Henry, J. Fitchett, 2001, Investigative ophthalmology & visual science.

Population pharmacokinetics and pharmacodynamics of IONIS-GCGRRx, an antisense oligonucleotide for type 2 diabetes mellitus: a red blood cell lifespan model

Richard Geary, S. Bhanot, S. Henry, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl–Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates

Y. Hua, A. Krainer, N. York, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Fomivirsen

S. Henry, R. Geary, L. Grillone, 2002, Clinical pharmacokinetics.

Impurities in Oligonucleotide Drug Substances and Drug Products.

S. Henry, A. Teasdale, J. Foy, 2017, Nucleic acid therapeutics.

Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.

M. Graham, S. Henry, R. Yu, 2016, Nucleic acid therapeutics.

Toxicology of Oligonucleotide Therapeutics and Understanding the Relevance of the Toxicities

A. Levin, S. Henry, 2010 .

Assessment of the Effects of ISIS 2302, an Anti-Sense Inhibitor of Human ICAM-1, on Cellular and Humoral Immunity in Mice

A. Levin, S. Henry, J. Mennear, 2006, Journal of immunotoxicology.

Mechanistic Understanding for the Greater Sensitivity of Monkeys to Antisense Oligonucleotide–Mediated Complement Activation Compared with Humans

P. Reynolds, S. Henry, A. Chappell, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in mice.

P. Adamson, B. Monia, S. Henry, 2016, Immunobiology.

Antisense Oligonucleotide-Related Macrovesicular Vacuolation of Hippocampal Neurons in Nonhuman Primates

J. Fikes, S. Henry, W. Meier, 2022, Toxicologic pathology.